Advisors

Scientific Advisory Board (SAB)

Paul Avillach, MD, PhD. Assistant Professor in Biomedical Informatics and Paediatrics at Harvard Medical School


Paul Avillach  is Assistant Professor of Epidemiology. Department of Epidemiology | Harvard T.H. Chan School of Public Health, and he holds an MD in public health and epidemiology and a PhD in biomedical informatics. Avillach's research focuses on the development of novel methods and techniques for the integration of multiple heterogeneous clinic cohorts, electronic health records data, and multiple types of genomics data to encompass biological observations. He is PI and Co-Investigator on several large projects at the Department of Biomedical Informatics at Harvard Medical School, including the BD2K PIC-SURE Center of Excellence, the Global Rare Diseases Registry project, the PCORI ARCH project, the PCORI Phelan-Mcdermid Syndrome project, NIH Undiagnosed Diseases Network (UDN) coordinating center, NIH Data Commons and NHLBI Data Stage project.

Josep V. Castell, MD, PhD. Professor at Faculty of Medicine of the IIS Hospital Universitario La Fe in Valencia


Dr. Castell is the Director of Research at the University Hospital La Fe and Head of the Unit of Experimental Hepatology of the Institute of Health Research of the University Hospital La Fe, of Valencia.

Hennicke Kamp, PhD. Head of Services Experimental Toxicology and Ecology at BASF SE


Hennicke Kamp works at BASF SE since 2010, previously he worked as a Toxicology Consultant for Metanomics GmbH from 2008 to 2010. He holds a PhD in Food Toxicology at the Technical University of Kaiserslautern.

Michael Merz, MD. Scientific Associate at Zurich University Hospital


Dr. Michael Merz is a clinical pharmacologist, with his main focus on drug safety during the past ten years. He worked as phase 1 investigator and Head of Phase 1 clinic for Quintiles and joined Novartis Pharma as Clinical Pharmacology Expert in 1998. At Novartis, he was Head of Modeling and Simulation in Clinical Pharmacology, worked as Senior Medical Safety Expert in Clinical Safety, and led the Systems Toxicology Section in Preclinical Safety. He set up the company’s liver safety expert team in 2008 and has been leading the group until April 2017. Since May 2017, he is working as a scientific associate at Zurich University Hospital, and as a consultant for the pharmaceutical industry, specializing in assessment and management of drug-induced liver injury.

Jean-Marc Vidal, MD. Assistant Professor in Pathology (APHP, Paris)


Jean-Marc Vidal is Doctor of Medicine (MD), Toxicology, Pathology & Regulatory. He works as a Toxicologist in the Pharmaceutical Industry during over 11 years. He is also Non-clinical Senior Scientific Officer at the European Medicines Agency (EMA) for more than 16 years.

Ethics Advisory Board (EAB)

Magí Farré, MD, PhD. Doctor of Medicine. Head Clinical Pharmacology Unit at Hospital Universitari Germans Trias i Pujol


Magí Farré is Professor of Pharmacology at Universitat Autonoma de Barcelona. He is Member of the Clinical Commission of the National Plan on Drugs from the Spanish Ministry of Health. Dr Farré’s main research area is clinical pharmacology of drug abuse, including novel psychoactive substances. He has experience in clinical trials in healthy subjects and patients, bioethics and methodology of clinical investigation.

Twitter

Latest News

Contact









Newsletter